Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) Debt to Equity (2016 - 2023)

Arcadia Biosciences (RKDA) has disclosed Debt to Equity for 10 consecutive years, with $0.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Debt to Equity fell 60.61% year-over-year to $0.0, compared with a TTM value of $0.0 through Mar 2023, down 60.61%, and an annual FY2022 reading of $0.0, up 11.95% over the prior year.
  • Debt to Equity was $0.0 for Q1 2023 at Arcadia Biosciences, down from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.27 in Q3 2020 and bottomed at $0.0 in Q1 2023.
  • Average Debt to Equity over 5 years is $0.04, with a median of $0.0 recorded in 2021.
  • The sharpest move saw Debt to Equity surged 16968.63% in 2020, then plummeted 98.95% in 2021.
  • Year by year, Debt to Equity stood at $0.02 in 2019, then soared by 535.71% to $0.11 in 2020, then crashed by 98.17% to $0.0 in 2021, then rose by 11.95% to $0.0 in 2022, then tumbled by 60.87% to $0.0 in 2023.
  • Business Quant data shows Debt to Equity for RKDA at $0.0 in Q1 2023, $0.0 in Q4 2022, and $0.0 in Q3 2022.